NEW YORK, Nov. 20, 2017 /PRNewswire/ -- If you want a Stock Review on ACHN, ADRO, AGIO, or ALNY then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Pre-market, DailyStockTracker.com observes Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Aduro BioTech Inc. (NASDAQ: ADRO), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), and Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY). These stocks are part of the Biotechnology sector, which harnesses biological processes to create technologies and products for a wide variety of challenges, from expanding crop sizes to treating disease. These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at:
New Haven, Connecticut headquartered Achillion Pharmaceuticals Inc.'s shares dropped 3.65%, finishing last Friday's session at $3.43. A total volume of 2.00 million shares was traded, which was above their three months average volume of 1.74 million shares. The stock is trading below its 50-day moving average by 16.59%. Additionally, shares of Achillion Pharma, which discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the US and internationally, have a Relative Strength Index (RSI) of 39.20.
On November 15th, 2017, Achillion Pharma announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson & Johnson Innovation-JJDC, Inc., which shares constitute all of the latter's equity position in ACHN, at a public offering price of $2.75 per share. The offering is expected to close on November 20th, 2017, subject to the satisfaction of customary closing conditions. Your complete research report on ACHN can be retrieved for free at:
On Friday, shares in Berkeley, California headquartered Aduro BioTech Inc. ended the session 2.22% lower at $8.80. The stock recorded a trading volume of 373,989 shares. The Company's shares are trading below their 50-day moving average by 8.69%. Moreover, shares of Aduro BioTech, which focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases, have an RSI of 51.69.
On October 31st, 2017, Aduro BioTech reported financial results for Q3 2017. Revenue for Q3 2017 was $3.8 million, net loss was $24.5 million, and income tax benefit was $3.9 million. R&D expenses were $24.5 million for the quarter and G&A expenses were $8.5 million. Cash, cash equivalents, and marketable securities totaled $373.5 million at September 30th, 2017. A free report on ADRO is just a click away at:
Cambridge, Massachusetts headquartered Agios Pharmaceuticals Inc.'s stock climbed 0.02%, to close the day at $59.64 with a total trading volume of 202,220 shares. The Company's shares have advanced 8.22% over the previous three months and 42.92% since the start of this year. The stock is trading 5.46% above its 200-day moving average. Additionally, shares of Agios Pharma have an RSI of 33.37.
On November 01st, 2017, Agios Pharma announced that new data from its lead programs will be presented at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, to be held from December 09th, 2017, to December 12th, 2017, in Atlanta. In total, four abstracts led by the Company, which describe new clinical data from its cancer and rare genetic diseases programs have been accepted for presentation at ASH. Two additional abstracts from Celgene and Boston Children's Hospital have also been accepted. Sign up for your complimentary research report on AGIO at:
Shares in Cambridge, Massachusetts headquartered Alnylam Pharmaceuticals Inc. recorded a trading volume of 901,011 shares. The stock ended at $127.51, climbing 0.89% from the last trading session. The Company's shares have gained 10.27% in the past month, 50.58% over the previous three months, and 240.57% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 10.97% and 63.48%, respectively. Furthermore, shares of Alnylam Pharma, which discovers, develops, and commercializes novel therapeutics based on RNA interference, have an RSI of 53.07.
On November 09th, 2017, research firm JP Morgan upgraded the Company's stock rating from 'Neutral' to 'Overweight'.
On November 16th, 2017, Alnylam Pharma announced the closing of the Company's previously announced underwritten registered public offering of 6,440,000 shares of its common stock, including 840,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a public offering price of $125.00 per share. The aggregate gross proceeds to the Company from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be $805 million. Register for free on DailyStockTracker.com and download the latest research report on ALNY at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.